Tags

Type your tag names separated by a space and hit enter

The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
Br J Pharmacol. 2020 11; 177(21):4921-4930.BJ

Abstract

COVID-19, the illness caused by SARS-CoV-2, has a wide-ranging clinical spectrum that, in the worst-case scenario, involves a rapid progression to severe acute respiratory syndrome and death. Epidemiological data show that obesity and diabetes are among the main risk factors associated with high morbidity and mortality. The increased susceptibility to SARS-CoV-2 infection documented in obesity-related metabolic derangements argues for initial defects in defence mechanisms, most likely due to an elevated systemic metabolic inflammation ("metaflammation"). The NLRP3 inflammasome is a master regulator of metaflammation and has a pivotal role in the pathophysiology of either obesity or diabetes. Here, we discuss the most recent findings suggesting contribution of NLRP3 inflammasome to the increase in complications in COVID-19 patients with diabesity. We also review current pharmacological strategies for COVID-19, focusing on treatments whose efficacy could be due, at least in part, to interference with the activation of the NLRP3 inflammasome. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Department of Neuroscience Rita Levi Montalcini, University of Turin, Turin, Italy. University of Turin, Neuroscience Institute of the Cavalieri-Ottolenghi Foundation, Orbassano (TORINO), Italy.Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.Department of Drug Science and Technology, University of Turin, Turin, Italy.Department of Neuroscience Rita Levi Montalcini, University of Turin, Turin, Italy. University of Turin, Neuroscience Institute of the Cavalieri-Ottolenghi Foundation, Orbassano (TORINO), Italy.Department of Science, University of Basilicata, Potenza, Italy.William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.Department of Drug Science and Technology, University of Turin, Turin, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32776354

Citation

Bertocchi, Ilaria, et al. "The Hidden Role of NLRP3 Inflammasome in Obesity-related COVID-19 Exacerbations: Lessons for Drug Repurposing." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4921-4930.
Bertocchi I, Foglietta F, Collotta D, et al. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. Br J Pharmacol. 2020;177(21):4921-4930.
Bertocchi, I., Foglietta, F., Collotta, D., Eva, C., Brancaleone, V., Thiemermann, C., & Collino, M. (2020). The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. British Journal of Pharmacology, 177(21), 4921-4930. https://doi.org/10.1111/bph.15229
Bertocchi I, et al. The Hidden Role of NLRP3 Inflammasome in Obesity-related COVID-19 Exacerbations: Lessons for Drug Repurposing. Br J Pharmacol. 2020;177(21):4921-4930. PubMed PMID: 32776354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. AU - Bertocchi,Ilaria, AU - Foglietta,Federica, AU - Collotta,Debora, AU - Eva,Carola, AU - Brancaleone,Vincenzo, AU - Thiemermann,Christoph, AU - Collino,Massimo, Y1 - 2020/08/26/ PY - 2020/06/25/received PY - 2020/07/17/revised PY - 2020/08/02/accepted PY - 2020/8/11/pubmed PY - 2020/10/28/medline PY - 2020/8/11/entrez KW - COVID-19 KW - diabetes KW - inflammation KW - repurposing SP - 4921 EP - 4930 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - COVID-19, the illness caused by SARS-CoV-2, has a wide-ranging clinical spectrum that, in the worst-case scenario, involves a rapid progression to severe acute respiratory syndrome and death. Epidemiological data show that obesity and diabetes are among the main risk factors associated with high morbidity and mortality. The increased susceptibility to SARS-CoV-2 infection documented in obesity-related metabolic derangements argues for initial defects in defence mechanisms, most likely due to an elevated systemic metabolic inflammation ("metaflammation"). The NLRP3 inflammasome is a master regulator of metaflammation and has a pivotal role in the pathophysiology of either obesity or diabetes. Here, we discuss the most recent findings suggesting contribution of NLRP3 inflammasome to the increase in complications in COVID-19 patients with diabesity. We also review current pharmacological strategies for COVID-19, focusing on treatments whose efficacy could be due, at least in part, to interference with the activation of the NLRP3 inflammasome. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32776354/The_hidden_role_of_NLRP3_inflammasome_in_obesity_related_COVID_19_exacerbations:_Lessons_for_drug_repurposing_ L2 - https://doi.org/10.1111/bph.15229 DB - PRIME DP - Unbound Medicine ER -